STOCKHOLM, Sept. 27, 2021 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that the company's Phase III clinical study of its drug candidate AKP02 for the treatment of psoriasis has been approved by the Indian Medical Products Agency and is ready to start. The main purpose of the study is to compare the therapeutic efficacy of AKP02 with Enstilar, the current market leader, for mild to moderate psoriasis. As Lipidor previously announced, results from the study are expected in the first half of 2022.
The registration-based Phase III clinical study with AKP02 comprises a total of 294 patients and is being conducted at twelve clinics in India. The trial is fully funded with existing cash and is conducted by Cadila Pharmaceuticals, a leading Indian pharmaceutical company with extensive CRO capacity. Cadila Pharmaceuticals has demonstrated through the successful Phase III study with the predecessor AKP01 that they can effectively recruit patients, administer a clinical trial and report clinical study results. The aim with AKP02 is to offer a patient-friendly, spray-based treatment for mild to moderate psoriasis.
The drug candidate AKP02 combines calcipotriol and betamethasone and is based on Lipidor's patented AKVANO® technology. Positive results from the Phase III study with the drug candidate AKP01, based solely on calcipotriol, show that Lipidor's AKVANO® technology works well for the treatment of psoriasis. The preclinical studies carried out by Lipidor also show that betamethasone works well with AKVANO® - a positive requirement for the second drug candidate, which combines calcipotriol and betamethasone.
The purpose of the Phase III study with AKP02 is to demonstrate good therapeutic efficacy for the treatment of mild to moderate psoriasis on both the body and scalp. Lipidor has chosen to compare the sprayable drug candidate AKP02 with Enstilar which is a commonly prescribed preparation in foam form for topical treatment of this indication, and which contains the same combination of active substances as AKP02. In order to reach a larger patient population, the scalp has also been included in the study. Psoriasis on the scalp, which often is affected, can consist of anything from weak to severe scale formation and cause varying degrees of itching.
The study will also measure quality of life and patient satisfaction in order to demonstrate associated benefits of AKP02. The observer-blind and placebo-controlled Phase III study is expected to have the first patient in-treatment during this fall with reporting in the first half of 2022.
On July 1, 2021 Lipidor announced that the company had signed a license agreement under which Lipidor grants RELIFE S.r.l., part of leading international pharmaceutical company, Menarini Group, exclusive rights to register, promote, distribute, and market the drug candidates AKP01 and AKP02 for the treatment of psoriasis in EU, Turkey, UK, Switzerland, CIS, and Balkan countries. Lipidor and RELIFE collaborate to make the two topical drug candidates available for the treatment of mild to moderate psoriasis.
Lipidor's partner Aurena Laboratories, one of the company's two large industrial owners, will be responsible for the commercial production of the products.
"We have high hopes for a successful Phase III clinical study with the psoriasis candidate AKP02 and we are looking forward to the study results," says Ola Holmlund, CEO of Lipidor. "We are pleased to have recently signed an exclusive license agreement with RELIFE, a company in the Menarini Group which has a strong European and global presence. Altogether, this strengthens our quest to make these innovative new drug candidates AKP01 and AKP02 available to psoriasis patients in the hope that they may improve the treatment of their condition and their quality of life."
In light of the outbreak of the coronavirus and Covid-19, Lipidor is closely monitoring developments and taking measures to minimize or eliminate the impact on the company's operations. To date, the Covid-19 pandemic has had a limited effect on Lipidor's operations, but the company may need to revise its schedules if the pandemic is prolonged.
This disclosure contains information that Lipidor is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-09-2021 10:55 CET.
CONTACT:
For more information, please contact
Ola Holmlund, CEO
Phone: +46 72 50 70 369
E-mail: ola.holmlund@lipidor.se
Certified Adviser
Erik Penser Bank AB
Telefon: +46 (0)8 463 83 00
E-post: certifiedadviser@penser.se
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
210927 Lipidor PR AKP02 Phase III EN |
